Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

InfiniCare, an AI-powered new drug R&D platform, receives Pre-A round investment from Lizhu Pharmaceutical.

Published Time:

2021-02-05

On February 5, 2021, Beijing Infinite Intelligence Pharma Technology Co., Ltd. (Infinite Intelligence Pharma) announced that it had received Pre-A round investment from Zhuhai Lizhu Pharmaceutical Equity Investment Management Co., Ltd., a wholly-owned investment platform of Lizhu Pharmaceutical (1513.HK, 000513.SZ).

 

According to Infinite Intelligence Pharma, with the support of the angel round investment from CAS Star and China Economic and Technical International Cooperation Group in August 2019, Infinite Intelligence Pharma's AI new drug development platform "PharmaMind" has taken shape. This platform integrates the most cutting-edge artificial intelligence-driven drug design (AIDD) and the new generation of computer-aided drug design (CADD) technologies, deeply covering the entire process from target discovery to pre-clinical candidate compounds. "PharmaMind" performs precise computational predictions of the multi-dimensional properties of the designed compounds, significantly improving the level of innovative drug R&D and the success rate of early-stage R&D from the source, meeting the urgent needs of the pharmaceutical industry for efficiency improvement and acceleration.

 

Dr. Pei Jianfeng, founder of Infinite Intelligence Pharma said: "The development of the third wave of artificial intelligence technology is in full swing, significantly changing human lifestyles and the paradigm of scientific and technological research and development. In the near future, it is expected to make breakthroughs in the field of new drug research and development. Infinite Intelligence Pharma is committed to promoting the development of efficient and powerful AI+ new drug R&D technology and platforms, with the mission of reducing the overall average cost of new drug R&D in the global pharmaceutical industry to less than 1/10 of the original cost. This round of financing will be used to upgrade the team, improve the intelligent drug R&D system, and expand the R&D pipeline to better serve global pharmaceutical companies, biotechnology companies, and partners. Infinite Intelligence Pharma also expects to use this round of financing to achieve world-class breakthroughs in AI+ new drug R&D technology and new drug R&D pipelines."

 

Dr. Liu Jianing, Chief Investment Officer of Lizhu Pharmaceutical said: "The global pharmaceutical industry urgently needs AI+ new drug R&D companies that can truly understand the needs of drug R&D and design innovative drug molecules with clinical advantages. We highly recognize Infinite Intelligence Pharma's team's technical capabilities and R&D direction in the AI+ new drug R&D platform. In its early stages, Infinite Intelligence Pharma has demonstrated a deep understanding and efficient execution of how AI can effectively empower new drug R&D, and the developed R&D module system and algorithms are at the leading level in the international industry. Lizhu Pharmaceutical Group is very fortunate to find such a long-term partner to jointly solve the pain points in new drug R&D."

 

 

About Beijing Infinite Intelligence Pharma Technology Co., Ltd.

 
 
The Infinite Intelligence Pharma team brings together top domestic experts in drug design and AI drug research, and was among the earliest in the world and the first in China to apply the most cutting-edge AI technology to new drug R&D. In the past year and a half, Infinite Intelligence Pharma has transformed the team's past successful technological experience into an AI new drug R&D system with independent intellectual property rights—PharmaMind.
 
PharmaMind is driven by data, experts, and technology, integrating expert intelligence, computational intelligence, perceptual intelligence, and cognitive intelligence. This system is developed and integrated with multiple underlying drug R&D tools for actual new drug R&D application scenarios, and can adapt to workflows based on actual business needs. The PharmaMind platform includes "system-based target discovery and combination analysis", "prediction of potential drug resistance mutation sites of drug targets", "structure-based protein druggability analysis", "structure-based 3D molecule generation", "high-precision ultra-high-throughput virtual screening", "high-druggability lead compound optimization", "multi-target de novo design and optimization", "allosteric drug/IDP drug design", and "high-precision compound structure image recognition", etc., which are practical core technologies at the global leading level. For unmet clinical needs, relying on the PharmaMind system, Infinite Intelligence Pharma is committed to promoting the development of new drug R&D pipelines that demonstrate the absolute advantages of AI technology. Currently, the progress of the R&D pipeline is smooth and has yielded encouraging results.
 
 

About Lizhu Pharmaceutical Group Co., Ltd.

 
 
Lizhu Pharmaceutical (1513.HK, 000513.SZ) is a leading domestic comprehensive pharmaceutical group integrating R&D, production, and sales. Zhuhai Lizhu Pharmaceutical Equity Investment Management Co., Ltd. is a wholly-owned investment platform established by Lizhu Pharmaceutical in Hengqin, Zhuhai, committed to discovering and supporting the R&D of leading Chinese pharmaceutical innovation technologies and products.
 
 

About CAS Star

 
 
CAS Star is oriented towards investing in "hard technology". In 2017, it established a medical investment team, mainly focusing on upstream and midstream R&D and manufacturing enterprises in the pharmaceutical and medical device industry chain. To date, it has participated in the investment of more than 20 early-stage enterprises. Investments include: Kexi Life, Bodong Medical, Wushuang Medical, CAS Microlight, Chuan Shi Biology, Deep Belief Biology, Zehui Biology, Lianxin Medical, etc. CAS Star's medical investment has made positive explorations in the transformation of scientific research achievements from universities. Among the invested enterprises, more than 10 are incubated from the Chinese Academy of Sciences, Peking University, Tsinghua University, Westlake University, Shanghai Jiao Tong University, etc.
 
 

About China Economic and Technical International Cooperation Group

 
 
Founded in 1993, China Economic and Technical International Cooperation Group is one of the earliest global cross-border VC institutions to enter the Asia-Pacific region. It focuses on investing in innovative projects at the forefront of global technology, actively promoting technological progress and the social application of technological achievements, and continuously creating value for society. China Economic and Technical International Cooperation Group continues to focus on three investment directions: health and medical care, enterprise intelligence, and sustainable development. It currently has offices in Silicon Valley, Beijing, and Taipei, and has invested in more than 400 companies, creating more than 100 successful cases of listing and mergers and acquisitions.
 
In the healthcare field, it focuses on innovative biopharmaceuticals, digital medicine, medical devices, and medical services. Previous investments include Aier Eye Hospital, Medi-Tech, Libang Instrument, and Leibotai Ke, all of which have been listed. Current investments include Boya Gene, Synthego, Kangsheng Global, Panorama Medicine, Infinite Intelligence Pharma, Engine Biosciences, DeepBiome, Kerry Corning, Rongxin Medical, Hengdao Pathology, Borui Kang, Anzhi Biomedicine, and Komed Diagnostics, among dozens of other excellent start-ups.
 
Source: DMAI Network